P. Of

### Nixon & Vanderhye rc.

ATTORNEY AT LAW

8TH FLOOR 1100 NORTH GLEBE ROAD ARLINGTON, VIRGINIA 22201-4714 TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100 WRITER'S DIRECT DIAL NUMBER:

(703) 816-4011

## FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

Atty Dkt.:	1579-548		
· • • • • • • • • • • • • • • • • • • •		Date:	August 6, 2003
To:	Exa	ıminer Stucker	- Group: 1648
Firm:		USP1	
Facsimile No.:		(703) 746	-5182
From:		Mary J. V	Vilson
	es (including cov ALL OF THE PAGES MEDIATELY AT (703-8	OR ENCOUNTER	36 DIFFICULTIES IN TRANSMISSION,
			Tabitha A. Trice
		F	ACSIMILE OPERATOR
s†			ORMATION DISCLOSURE (IN DUPLICATE) AND
MESSAGE:			
In re PATENT APPLIC	CATION OF:		
HAYNES et al Serial No.: 09/775,80 Filed: February 5, 200		14	

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhya, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSDEVER IS STRICTLY PROBIBITED. If you have received this facsimile in error, please immediately contact us by telephone to

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

ín	гΑ	Patent	Appl	ication	of

Atty Dkt. 1579-548

C# M#

HAYNES et al

Group Art Unit: 1648

Serial No. 09/775,805

Examiner: Stucker, J.

Filed: February 5, 2001

Date: August 6, 2003

Title:

HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

signature thereon.	ne adaciditent in the absence of any other	
Correspondence Address Indication Form Attached.		
Fees are attached as calculated below:  Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$ 0.0	20
Independent claims after amendment $0$ minus highest number previously paid for $3$ (at least $3$ ) = $0$ x \$ 84.00	\$ 0.0	0
If proper multiple dependent claims now added for first time, add \$280.00 (igno	ore improper) \$ 0.0	Ю
Petition is hereby made to extend the current due date so as to cover the filing paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months	s) \$ 0.0	
Terminal disclaimer enclosed, add \$ 110.00	\$ 0.0	)0
First/second submission after Final Rejection pursuant to 37 CFR 1.129(a Please enter the previously unentered , filed Submission attached	) (\$750.00) \$ 0.0	10
_	Subtotal \$ 0.0	)0
If "small entity," then enter half (1/2) of subtotal and subtract  Applicant claims "small entity" status.  Statement filed herew	-\$ 0.0	10
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$ 0.0	)()
Assignment Recording Fee (\$40.00)	\$ 0.0	)0
Other:	0.0	)0
	TOTAL FEE ENCLOSED \$ 0.0	Ю
The Commissioner is hereby authorized to charge any <u>deficiency</u> , or credit any asserted to be filed, or which should have been filed herewith (or with any pap firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.		
1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201-4714 Telephone: (700) 816-4000 Telephone: (700) 816-4000		
Facsimile: (703) 816-4100 MJW:tat Signature:	ery J. Wilson	_

In re Patent	Application	of
--------------	-------------	----

Atty Dkt. 1579-548

C# M#

HAYNES et al

Group Art Unit: 1648

Serial No. 09/775,805

Examiner: Stucker, J.

Filed: February 5, 2001

Date: August 6, 2003

Title: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby

Incorporated by reference and the signature below serves as the signature to the attachment in the absence signature thereon.	of any	other
☐ Correspondence Address Indication Form Attached.		
Fees are attached as calculated below:  Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)  Please enter the previously unentered , filed Submission attached	\$	0.00
Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract  Applicant claims "small entity" status.  Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$ .	0.00
Other:		0.00
TOTAL FEE ENCLOSED	\$	0.00
The Commissioner is hereby authorized to charge any <u>deficiency</u> , or credit any overpayment, in the fee(s) file asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.	id, or tion by	this
1100 North Glebe Road, 8 <sup>th</sup> Flodi NIXON & VANDERHYE P.C. Arlington, Virginia 22201-4714 By Atty: Mary J. Wilson, Reg. No. 32,955 Telephone: (703) 816-4000	<b>*</b> ••	
Facsimile: (703) 816-4100  MJW:tat  Signature:   NCENT J. Le. (5c)	<u>27</u>	7

_		Kandiaa i	Le		
in re Pa	itent App	lication	D1	Atty. Ref.:	1579-548
HAYNE	S et al			•	1648
Serial N	۷o. ۵	9/775,8	05	Group:	
Filed:	Febr	uary 5,	2001	Examiner:	Stucker, J.
For:	HUMAN	IMMUN	ODEFICIENCY VIRUS VACC	INE	
1 01.		}   	* * * * * * * *	* * * *	
$D \cap E$	iissioner Iox 1450 Indria, VA			August 6, 2	2003
Sir:	<u>şu</u>	PPLEM	ENTAL INFORMATION DISC	LOSURE ST	<u>ATEMENT</u>
	1.	PTO-14 [within	49 Pursuant to 37 CFR 1.976 months of filing or prior to 18	(b) It Office Action	n on the merits] N/C
	2.(a)	Ibofore	ent Pursuant to 37 CFR 1.97 Final Office Action or Allowan ent <u>or</u> Rule 17(p) fee)]	7(c) ace (requires l	Rule 97(e) N/C
$\boxtimes$	2 .(b)	Thefore	yment Pursuant to 37 CFR Final Office Action or Allowar ent or Rule 17(p) fee)]	1.97(c) nce (requires	Rule 97(e) <i>\$180.00</i>
	3.	Pursu [after l Stater	ant to 37 CFR 1.97(d) inal Office Action or Allowand ient <u>and</u> Rule 17(p) fee), but t	ce (requires R before final fe	sule 97(e) e payment] \$180.00

and

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1 98:

A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.
 This paper is submitted in accordance with:
 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
 8. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];

a) The required Statement made in item 8 below; or

D) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR \$1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

D) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

П

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

While no further fee is believed to be required, if the Office takes a different view, authorization is hereby given to charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

Mary J. Wilson

Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816 4100

	NIXON & VANDERHYE	PC3 Fax	:703-816-410	)N Aug e c	2003 15:5			
		1		nug g 2	.003 15:5	4 P.	. 07	
Sheet 1 of 1		Atty. I	Docket No.		rial No.			
		1570	9-548	n:	9/775,805	,		
INFOR	MATION DISCLOSURE CITATION	Applic			<i>31113</i> ,003	<u>'</u>		
		HAY	NES et al					
(Uşe	several sheets if necessary)	Filing	Filing Date Gro		oup	<del></del>		
		Febr	uary 5, 200	1 10	648	·		
			<del></del>		·	·		
*EXAMINER			U.S. PATENT	DOCUMENTS			Ell INC	DATE
INITIAL	DOCUMENT NUMBER	DATE	·	NAME	CLASS	SUBCLASS	IF APPR	OPHIATE
	<del></del>	<del>                                     </del>	<del> </del>			<del> </del>		
	<del>                                     </del>	╂	<del> </del>					
	-	₩	<del> </del>			ļ		
	<del></del>	1	<del></del>	<del></del>	<del></del>	ļ	<del></del>	
	ļ. —	₩	<b></b>			<b></b>		
	<del></del>	<del> </del> -				<del> </del>	ļ	
	<del></del>	<del>}</del>	<del> </del>		<del></del>			
	<del>                                     </del>	1			<del></del>	<del> </del>		
		<u> </u>						
		FOI	REIGN PATEN	T DOCUMENTS			TRANC	LATION
	DOCUMENT	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO
				000(1777)	7	000002.00	, 23	T-10-
		<u> </u>	<del></del>					
	<del></del>	<del> </del> -	<del> </del>		<del></del>	<del> </del>		<del> </del>
	4							
	OTUER DOG	IMENTS /	anleration Arret	or Title Data Dating	<u></u>	<u> </u>		L
	Wain-Hobson, "Is Anti-	penic Variation	on of HIV Impor	or, Title, Date, Pertine tant for AIDS and What I	<b>nt pages, e</b> Might Bc Exc	ccted in the l	hture?"	The
	Evolutionary Biology o	f Viruses. St	phen S. Morse	(ed), Raven Press, Ltd., N	ew York, pgs	. 185-209 (19	94)	
	<del></del>							
					<del></del>			
				·		·		
*Examiner				Date Considered				
	if reference considered, whether o	or not citation is it	1 conformance with M		ion if not in confo	mance and not	oneidered	Include
copy of this form	with next communication to applic	ation.				Form OTO ER		

In re Pate	ent Application of		•
HAYNES	et al	Atty. Ref.:	1579-548
Serial No	o. 09/775,8 <b>0</b> 5	Group:	1648
Filed:	February 5, 2001	Examiner:	Stucker, J.
For: H	IUMAN IMMUNODEFICIENCY VIRUS	VACCINE	
P.O. Box	sioner for Patents 1450 ia, VA 22313-1450	* * * * *	
Діфхилип	10, 77 22010	August 6, 2	9003
Sir:	SUPPLEMENTAL INFORMATION	DISCLOSURE STA	TEMENT
□ 1.	PTO-1449 Pursuant to 37 CFR (within 3 months of filing or prior		on the merits] <i>N/C</i>
2.(6	a) Statement Pursuant to 37 CFR [before Final Office Action or Alk Statement or Rule 17(p) fee)]	1.97(c) owance (requires Ru	ule 97(e) N/C
☑ 2.(	(b) Fee Payment Pursuant to 37 C [before Final Office Action or Allo Statement or Rule 17(p) fee)]	FR 1.97(c) owance (requires Ru	ule 97(e) \$180.00
□ 3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allow Statement and Rule 17(p) fee), but the statement and Rule 17(p) fee).	/ance (requires Rule out before final fee p	97(e) ayment] \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

冈 A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with: 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] 図 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and a) The required Statement made in item 8 below; or 冈 b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. П 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee paymentl; and П a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) The undersigned attorney of record hereby certifies under 37 C.F.R. \$1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each itemicontained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. While no further fee is believed to be required, if the Office takes a different view, authorization is hereby given to charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

By:

ary J. Wilson

Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

Sheet 1 of 1 INFORMATION DISCLOSURE CITATION		Appli	Atty. Docket No. Serial No.  1579-548 09/775,805  Applicant						
(Use	soveral sheets if necessary)	Filing	/NES et al		roup	IIIO			
		Feb	ruary 5, 2001		648				
			U.S. PATENT DOCU	MENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAM		CLASS	SUBCLASS	FILIN IF APPE	G DATE	
		<u> </u>							
								····	
		EO	REIGN PATENT DOC	IMENTO					
			EIGHTATEHT DOC	341C141 0		<del></del>	TRANS	LATION	
—	DOCUMENT	DATE	COUNT	RY	CLASS	SUBCLASS	YES	NO	
							<del></del>		
	OTUED DOOU	MENTS /1-	icluding Author, Title	Deta Portino	t nagae et				
	Wain-Hobson, "Is Antige Evolutionary Biology of	nic Variatio	on of HIV Important for A	AIDS and What M	light Be Exp	ected in the F	uture?", 94)	The	
		-			7				
*Examiner			Date	Considered					